• 4 Takeaways From The World Biosimilar Congress
    4 Takeaways From The World Biosimilar Congress

    Throughout this whirlwind two-day event, the panelists addressed the challenges of patient education and uptake, the pharmacovigilance of biosimilars, and how to navigate varying regulatory requirements in the global market. But there were four key messages relayed throughout this conference that are worth noting.

Navigating Brazil’s Emerging Biosimilar Market

The Latin American markets, and especially Brazil, hold great promise for biosimilar development, PlantForm CEO Don Stewart says. In recent years, many partnerships have been launched in Brazil between local and international companies to bolster the country’s biosimilar development. However, there are a number of things companies looking to forge joint ventures in Brazil need to keep in mind for success.

Some Biopharma Haven’t Caught Outsourcing Enthusiasm

I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

“Growing” Biosimilars: How Plants Bolster Manufacturing Efficiency

Roughly 15 to 20 years ago, a number of pharmaceutical companies raised money to employ tobacco technology in drug development. Unfortunately, this rush did not lead to the success many were hoping for. However, the successes of recent players in this space suggest pharma could be entering a new age in plant-based manufacturing.

Will Medicare Part D Make Biosimilar Manufacturers Pay?

Despite biosimilars’ reputation as cheaper alternatives to costly biologics, Medicare Part D patients likely won’t see great savings at least not right away. According to a recent Avelare Health report, there are two ways patients could see reduced biosimilar out-of-pocket costs. But one of these solutions could place a big burden on biosimilar manufacturers. 

More From Editor's Desk


More From Guest Contributors...


ICON Insight: Leveraging Patient Registries To Assess Safety And Product Performance In The Post-Approval Arena

The drug development path today is more challenging and expensive than ever. The cost of bringing a new drug to market is estimated at somewhere between $500 million and $1 billion. With this intense development investment, it's critical, then, for the drug to remain on the market after approval — an outcome that is not nearly as certain today as it was in decades past. Submitted by ICON Clinical Research

Material Compatibility With Vaporized Hydrogen Peroxide (VHP) Sterilization

Various sterilization methods (including gamma irradiation an  ethylene oxide) have been widely used for terminal medical device sterilization. No single method offers the perfect sterilization solution for every application. By G. McDonnell

More White Papers...


More Bioprocessing Posters...


More Webinars On-Demand...


Big Data Bioinformatics Conference May 26 - 27, 2016
Boston, CA
CRISPR & Genome Engineering Conference May 26 - 27, 2016
Boston, MA
Events Calendar